The relationship between plasma levels of lipoprotein(a) [Lp(a)], PCSK9 and their complex in hypercholesterolemic patients depends on the apolipoprotein(a) phenotype

被引：0
|
作者：
Klesareva, E. A. [1 ]
Afanasieva, O. I. [1 ]
Razova, O. A. [1 ]
Utkina, E. A. [1 ]
Afanasieva, M. I. [1 ]
Ezhov, M. V. [2 ]
Pokrovsky, S. N. [1 ]
机构：
[1] Natl Med Res Ctr Cardiol, Inst Expt Cardiol, Moscow, Russia
[2] Natl Med Res Ctr Cardiol, Inst Clin Cardiol, Moscow, Russia
来源：
EUROPEAN HEART JOURNAL | 2018年 / 39卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P6272
引用
收藏
页码：1305 / 1305
页数：1
相关论文
共 50 条
  • [21] Relationship Between Low-Density Lipoprotein Cholesterol and Lipoprotein(a) Lowering in Response to PCSK9 Inhibition With Evolocumab
    Shapiro, Michael D.
    Minnier, Jessica
    Tavori, Hagai
    Kassahun, Helina
    Flower, Andrea
    Somaratne, Ransi
    Fazio, Sergio
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2019, 8 (04):
  • [22] Plasma PCSK9 Levels are associated with the severity of coronary stenosis in patients with atherosclerosis
    Li, Sha
    Guo, Yuanlin
    Xu, Ruixia
    Zhang, Yan
    Zhu, Chenggang
    Sun, Jing
    Qing, Ping
    Wu, Naqiong
    Li, Jianjun
    CARDIOLOGY, 2014, 129 : 14 - 15
  • [23] Plasma PCSK9 levels are associated with the severity of coronary stenosis in patients with atherosclerosis
    Li, Sha
    Guo, Yuan-Lin
    Xu, Rui-Xia
    Zhang, Yan
    Zhu, Cheng-Gang
    Sun, Jing
    Qing, Ping
    Wu, Na-Qiong
    Li, Jian-Jun
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2014, 174 (03) : 863 - 864
  • [24] Lipoprotein(a) and Benefit of PCSK9 Inhibition in Emergency Complex Higher-risk and Indicated Patients
    Jin, Zhi-li
    He, Tao
    Peng, Li
    Wu, Xiao-yan
    Fan, Di
    Chen, Ming
    Fan, Yong-zhen
    Guo, Yuan-lin
    Lu, Zhi-bing
    Wang, Hai-rong
    CURRENT MEDICAL SCIENCE, 2023, 43 (06) : 1206 - 1212
  • [25] Lipoprotein(a) and Benefit of PCSK9 Inhibition in Emergency Complex Higher-risk and Indicated Patients
    Zhi-li Jin
    Tao He
    Li Peng
    Xiao-yan Wu
    Di Fan
    Ming Chen
    Yong-zhen Fan
    Yuan-lin Guo
    Zhi-bing Lu
    Hai-rong Wang
    Current Medical Science, 2023, 43 : 1206 - 1212
  • [26] Association between plasma levels of PCSK9 and the presence of coronary artery disease in Japanese
    Nose, Daisuke
    Shiga, Yuhei
    Ueda, Yoko
    Idemoto, Yoshiaki
    Tashiro, Kohei
    Suematsu, Yasusnori
    Kuwano, Takashi
    Kitajima, Ken
    Saku, Keijiro
    Miura, Shin-ichiro
    HEART AND VESSELS, 2019, 34 (01) : 19 - 28
  • [27] Relationship between PCSK9 and endothelial function in patients with acute myocardial infarction
    Cimaglia, Paolo
    Fortini, Francesca
    Sega, Francesco Vieceli Dalla
    Cardelli, Laura Sofia
    Massafra, Rodolfo Francesco
    Morelli, Cristina
    Trichilo, Michele
    Ferrari, Roberto
    Rizzo, Paola
    Campo, Gianluca
    NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES, 2022, 32 (09) : 2105 - 2111
  • [28] Relationship between "LDL-C", estimated true LDL-C, apolipoprotein B-100, and PCSK9 levels following lipoprotein(a) lowering with an antisense oligonucleotide
    Viney, Nicholas J.
    Yeang, Calvin
    Yang, Xiaohong
    Xia, Shuting
    Witztum, Joseph L.
    Tsimikas, Sotirios
    JOURNAL OF CLINICAL LIPIDOLOGY, 2018, 12 (03) : 702 - 710
  • [29] Having excess levels of PCSK9 is not sufficient to induce complex formation between PCSK9 and the LDL receptor (vol 545, pg 124, 2014)
    Wooten, Catherine J.
    Adcock, Audrey F.
    Agina-Obu, DaTonye I.
    Lopez, Dayami
    ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 2014, 562 : 122 - 122
  • [30] GREATER LIKELIHOOD OF REGRESSION OF CORONARY ATHEROSCLEROSIS WITH THE PCSK9 INHIBITOR, EVOLOCUMAB, IN PATIENTS WITH HIGHER LP(A) LEVELS
    Scherer, Daniel
    Puri, Rishi
    Ballantyne, Christie
    Cho, Leslie
    Brennan, Danielle
    Kassahun, Helina
    Somaratne, Ransi
    Wasserman, Scott
    Nissen, Steven
    Nicholls, Stephen
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2018, 71 (11) : 17 - 17
12345